Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug can restore social ability in schizophrenics

06.12.2007
The social behaviour of rats displaying schizophrenic tendencies is restored when they are treated with two new potential drugs that seem to have unique effects on dopaminergic signalling. This is a conclusion of a thesis from the Sahlgrenska Academy at Göteborg University in Sweden.

Schizophrenia is a severe psychiatric disorder with symptoms that include hallucinations and delusions. Other common effects are social withdrawal, lack of initiative, dulled emotions, and difficulty in experiencing pleasure.

"The treatment available for schizophrenic patients hardly ever relieves impairment of social function. If patients are to have satisfactory lives, we must find new drugs," says pharmacologist Johan Rung, who has studied the two drug candidates, OSU6162 and ACR16.

In the studies, rats were given a type of drug known for inducing a schizophrenia-like state in humans, and this reduced the rats' social behaviour. When the rats were given the two drug candidates, normal social behaviour was restored.

"This indicates that the two drugs can relieve the schizophrenic's lack of ability to interact socially, and also have positive effects on a number of other symptoms thought to be caused by the same underlying mechanisms," says Johan Rung.

In contrast to other drugs that only reduce dopaminergic signalling in the brain, the two new substances seem to be able to both reduce and strengthen the signalling, depending on the circumstances.

"This is a property that can be particularly beneficial in the treatment of schizophrenia. Different groups of symptoms can be linked to either elevated or reduced dopaminergic signalling in different parts of the brain," says Johan Rung.

More years of research lie ahead before doctors can prescribe the new substances as drugs for their patients. An international drug company has recently started to test ACR16 on patients. The other substance, OSU6162, has also been tested on a small number of schizophrenia patients, and the results are promising.

SCHIZOPHRENIA
Schizophrenia is a psychiatric disease that afflicts one percent of the population. There is no cure, but psychotic symptoms can be treated with psychopharmaceuticals. The onset usually occurs when people are in their twenties. The condition is often severe, and most patients never return to school or work.
For more information, please contact:
Johan Rung, pharmacologist, telephone: +46 (0)31-786 33 28, +46 (0)70-350 30 58, e-mail: johan.rung@psychiat.gu.se
Supervisor:
Associate Professor Maria Carlsson, telephone: +46 (0)31-786 33 28, e-mail: maria.carlsson@psychiat.gu.se
Doctor of Philosophy (Medicine) thesis at the Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation.

Title of thesis: Dopaminergic stabilizers for the treatment of schizophrenia; rat studies focusing on negative symptoms and mechanisms of action

Elin Lindström Claessen
Information Officer, Sahlgrenska Academy at Göteborg University
Telephone: +46 (0)31-786 3837, +46 (0)70-829 43 03
e-mail: elin.lindstrom@sahlgrenska.gu.se
The Sahlgrenska Academy is the faculty of health sciences at Göteborg University. Education and research are conducted within the fields of medicine, odontology and health care sciences. About 4,000 undergraduate students and 1,000 postgraduate students are enrolled at the Sahlgrenska Academy. The Academy has 1,500 employees, 850 of which are researchers and/or teachers.

Elin Lindström Classeb | idw
Further information:
http://www.vr.se

Further reports about: Academy Rung Sahlgrenska patients schizophrenic signalling symptoms

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>